In many experimental studies, induction of Cox 2 has been proven to promote cell growth and prevent apoptosis. Thus, inhibition of Cox 2 claims to be a successful strategy in preventing and treating cancer. In this review, Western blot analysis and RTPCR showed a specific loss of Cox 2 after BV therapy, while low inducible Cox 1 didn’t affect (-)-MK 801 any attention. These results might suggest that downregulation of Cox 2 inhibits induced apoptosis and cell growth. FasL is a type II transmembrane protein that plays a crucial role in immune homeostasis by presenting to the receptor Fas, a member of the cyst necrosis factor receptor superfamily, and inducing apoptosis. It’s recognized that the interaction between Fas and FasL activates caspase 8 and caspase 3, which leads to apoptosis. Thus, we examined whether BV causes up-regulation of Fas and FasL expression. As shown in Fig. 7B, BV treatment dramatically increased the degrees of Fas and FasL mRNA and protein more than 2 ug/ml at 48 h, suggesting that the results of BV in U937 are connected with Fas and FasL expression. The pieces comprising hTR, hTERT, Endosymbiotic theory telomerase and TEP 1, are essential determinants of telomerase activation. We therefore examined the changes in the mRNA expression in therapy with BV using RT PCR, to analyze the consequence of BV on a telomerase related gene. As shown in Fig. 7C, mRNA levels of hTERTalone considerably decreased, however not hTR and TEP 1, with therapy of BV in a dosedependent manner. In line with these results, more than 2 ug/ml led to a loss of the protein. These data may suggest that BV induces a decrease of telomerase activity through downregulation of hTERT. This time requires further study using apoptosisinducing inhibitors or overexpression of antiapoptotic protein, such as Bcl 2, in cancer cells, because mechanism of BV caused apoptosis, especially in leukemic ALK inhibitor cancer cells, has yet to be decided. Therefore, in the present research, we first examined how the apoptotic mechanismof BVwas assessed in human leukemic U937 cells. U937 cells treated with increased than 2 ug/ml showed a dose dependent inhibition of the growth, and cell shrinkage and nuclear condensation. Flow cytometric analysis also unveiled that BV therapy results in an increase of sub G1 DNA content, which is suggestive of apoptosis. These results suggest thatBV stimulated apoptosis contributes to the growth inhibition of U937 cells. Caspases, a family of cysteine proteases, are integrated parts of the apoptotic pathway, caspase 3 particularly, when activated, has several cellular targets that, when severed and/or activated, produce the morphologic characteristics of apoptosis.